CINCINNATI, May 19, 2022 (GLOBE NEWSWIRE) — Blue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing vaccines, announces collaboration with the Multidisciplinary R&D Center in Immunobiologics (“CeRDI”), an initiative of Instituto Butantan (“Butantan”). Through this partnership, Butantan, a leading Brazilian producer of immunobiological products and vaccines, and BWV will develop the universal influenza vaccine candidate, BWV-101, in Brazil.

Instituto Butantan received a grant from the Sao Paulo State Research Foundation (FAPESP) to develop BWV’s universal influenza vaccine candidate in Brazil. This project grant is part of a larger consortium through CeRDI to develop a centralized resource to achieve national autonomy in the manufacture and development of vaccines and biologicals. The consortium includes several research groups across universities, including the University of Oxford, as well as other private companies. Through this collaboration, CeRDI is committed to advancing vaccines based on adjuvant formulation and new vaccines based on cell culture.

“We are extremely honored to be part of this joint effort to develop our vaccine candidate in Brazil,” said Joseph Hernandez, CEO of Blue Water Vaccines. “Instituto Butantan is one of the main vaccine producers in Brazil and is highly respected around the world. We hope to reach new heights in vaccine manufacturing and development through this collaboration.

Blue Water Vaccines is developing a universal influenza vaccine that could potentially provide lifelong protection against influenza, including pandemic strains like the 1918 pandemic and 2009 swine flu. University of Oxford scientists have identified epitopes with limited variability in the head region of the hemagglutinin protein. These epitopes are naturally targeted by the immune system, and vaccination studies have shown that regions of influenza viruses that circulated in 2006 and 1977 were able to protect against infection from an influenza virus that last circulated in 1934. .

The vaccine is produced using a E.coli expression platform allowing more cost-effective and faster production of the vaccine, compared to current influenza production models.

About Blue Water Vaccines

Blue Water Vaccines, Inc. is a biopharmaceutical company focused on developing transformational vaccines to address important global health challenges. Based in Cincinnati, OH, the company owns the rights to proprietary technology developed at Oxford University, Cincinnati Children’s Hospital Medical Center (CCHMC), and St. Jude Children’s Hospital. The company is developing a universal influenza vaccine that will provide protection against all virulent strains in addition to licensing a novel S&P Nanoparticle Versatile Virus Particle (VLP) Vaccine Platform S&P of CCHMC to develop vaccines against several infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a vaccine candidate against Streptococcus pneumoniae (pneumococcus), designed to specifically prevent highly infectious middle ear infections, known as acute otitis media (AOM), in children. For more information, visit www.bluewatervaccines.com.

About Instituto Butantan

Instituto Butantan is the main producer of immunobiologicals and vaccines in Brazil. Instituto Butantan carries out scientific missions at home and abroad through the Pan American Health Organization, the World Health Organization, UNICEF and the United Nations. The Institute collaborates with other agencies of the State Secretariat of Health of São Paulo and the Brazilian Ministry of Health for the improvement of overall health in Brazil. It works in partnership with various businesses, universities and philanthropic entities to achieve its institutional public health objectives. For more information, please visit the Institute’s website at www.butantan.gov.br or contact the press service at (+55 11) 2627-9606 / 9866 / 9426 or by e-mail to [email protected]

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements can be identified by the use of forward-looking terms such as “anticipate”, “believe”, “expect”, ” estimate”, “expect”, and “intend”, among others. These forward-looking statements are based on BWV’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by these forward-looking statements. These factors include, but are not limited to, risks related to the development of BWV’s vaccine candidates, including but not limited to BWV-301; failure to obtain FDA clearances or approvals and failure to comply with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks relating to the timing and progress of clinical development of our product candidates; our need for additional funding; uncertainties of patent protection and litigation; uncertainties of reimbursement by the government or third-party payer; limited research and development efforts and reliance on third parties; and significant competition. As with any vaccine under development, the development, regulatory approval and commercialization of new products involve significant risks. BWV does not undertake to update or revise any forward-looking statement. Investors should read the risk factors set forth in BWV’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2022, and periodic reports filed with the SEC as of the date hereof. All of BWV’s forward-looking statements are expressly qualified by all such risk factors and other caveats. The information presented here is only valid as of the date thereof.

Contact information:
Media Relations
513-620-4101
Email: [email protected]